产品
编 号：F429197
分子式：C9H17NO3
分子量：187.24
分子式：C9H17NO3
分子量：187.24
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 69542-93-4
产品详情
生物活性：
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain.
体内研究：
Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions.Animal Model:Adult male Sprague-Dawley CD rats (200-250 g)
Dosage:200 mg/kg
Administration:i.p.; twice a day for 4 days and 1 hour before killing on the 5th day
Result:Prevented the effects of foot-shock stress on CRF concentration in both brain regions. Reduced by 52% the CRF concentration in the hypothalamus but had no effect on that in the cerebral cortex.
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain.
体内研究：
Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions.Animal Model:Adult male Sprague-Dawley CD rats (200-250 g)
Dosage:200 mg/kg
Administration:i.p.; twice a day for 4 days and 1 hour before killing on the 5th day
Result:Prevented the effects of foot-shock stress on CRF concentration in both brain regions. Reduced by 52% the CRF concentration in the hypothalamus but had no effect on that in the cerebral cortex.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备